

Protalix BioTherapeutics, Inc.  
Form 8-K  
October 19, 2015

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): October 19, 2015**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

<b>Florida</b>	<b>001-33357</b>	<b>65-0643773</b>
<b>(State or other jurisdiction</b>		<b>(IRS Employer</b>
<b>of incorporation)</b>	<b>(Commission File Number)</b>	<b>Identification No.)</b>



**Item 8.01. Other Events**

On October 19, 2015, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing positive long term data from the 0.2mg, or lowest dose, of the Company’s phase I/II dose ranging clinical trial of PRX-102 for the treatment of Fabry disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated October 19, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: October 19, 2015 By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: President and  
Chief Executive Officer